Abbott To FDA: Resolve 505(b)(2) Issues Before Approving Depakote Competitors
This article was originally published in The Pink Sheet Daily
Executive Summary
Andrx’ NDA for delayed-release valproate sodium differs from Depakote only in active ingredient and raises the same type of public policy concerns FDA identified in its October 2003 analysis of the approval pathway, an Abbott citizen petition states.
You may also be interested in...
Endpoint Milestone In AML: Kronos’ Entospletinib Trial Will Rely On Residual Disease
Phase III study in newly diagnosed patients with NPM1-mutated AML could enable Kronos’ SYK-inhibitor to reach market two years earlier under accelerated approval than it would under a traditional endpoint, company says.
BrainStorm’s Phase III Data Do Not Support Clinical Benefit Of NurOwn In ALS, US FDA Says
Agency’s unusual public statement about an investigational product's development status may be aimed at countering bullish comments from the sponsor; FDA cites failure of pivotal trial on the primary and secondary endpoints and ‘modest excess in deaths’ with the cell therapy.
ACIP Shies Away From COVID-19 Vaccine Comparative Efficacy And Safety Evaluations
The CDC panel’s mandate is to make recommendations for each specific vaccine brought forward, not ‘comparing two, three or four vaccines, and coming up with specific recommendations for each one independent of the other,’ chairman Jose Romero says as ACIP recommends use of Janssen’s COVID-19 vaccine under EUA.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: